Drugs.com - Clinical Trials

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

SAN DIEGO – January 10, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant, a novel...

Feb 9, 2025 - 21:44
 0
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
SAN DIEGO – January 10, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant, a novel...
Read More

Tags:

Previous Article

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to ...

Next Article

Research and Pipeline Research Pfizer’s Sasanlimab in Combination with BCG Impro...

Related Posts

Azer-cel Granted FDA Fast Track Designation in Blood Cancer DLBCL

Azer-cel Granted FDA Fast Track Designation in Blood Ca...

Mar 21, 2025  0

Sarepta Therapeutics Shares Safety Update on Elevidys

Sarepta Therapeutics Shares Safety Update on Elevidys

Mar 18, 2025  0

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Receives U.S. FDA Fast Track Designa...

Apr 14, 2025  0